Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

NEWS

A revolution in the fight against problematic skin

29. 08. 2023

Our subsidiary Aumed Pharma a.s. is launching a revolutionary bacteriophage-based product in the fight against problematic skin. Phage Glow is...

The new website of our subsidiary Aumed Pharma a.s.

29. 08. 2023

Our subsidiary Aumed Pharma is launching a new website (www.aumedpharma.cz) where you can purchase our specially developed nutritional supplements and...

AUMED joins the association fighting against antibiotic resistance

18. 07. 2023

A representative of AUMED participated in the meeting to establish the association Czech Antibiotic Resistance Platform (CZEPAR). The course of...

AUMED, a.s. successfully completed the project entitled “Transfer factor TFI – Medicinal product”

28. 06. 2023

AUMED, a.s. successfully completed the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As part of the project,...

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As...

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a...

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company....

Successful completion of the TRIO project „Development of a new dosage form for oral vaccine administration”

18. 05. 2022

AUMED, a.s. successfully completed a multi-year project of the research and development support program of the Ministry of Industry and...

AUMED, a.s. received a grant for the Innovation Project entitled “TFI Transfer Factor – Medicine”

18. 05. 2022

AUMED, a.s. received a grant in the Operational Program Enterprise and Innovation for Competitiveness under the Innovation Call – Innovation...

PCR GARGLING KIT

07. 05. 2021

AUMED, a.s. launches its own self-sampling set based on the principle of gargling of the oral cavity and pharynx. The...

AUMED a.s. received support for the production of a diagnostic kit for covid-19

13. 12. 2020

AUMED a.s. received support for the project PRODUCTION OF DIAGNOSTIC KIT FOR COVID-19 ON THE LAMP PRINCIPLE within the TECHNOLOGY...

New sampling set GARGTEST

30. 11. 2020

AUMED, a.s. collaborated on the development of a new self-sampling set based on the principle of gargling of the oral...

“COVID-19” TESTING FOR COMPANIES

22. 10. 2020

AUMED a.s. offers for companies a comprehensive solution for preventive testing of the SARS-CoV-2 virus (COVID-19). We provide sampling and...

Covid-19 diagnostics using a newly developed test – AUMED test RT-LAMP Assay SARS-CoV-2

01. 10. 2020

AUMED a.s. is involved in the fight against the Covid-19 pandemic. In cooperation with Protean s.r.o. and Institute of Molecular and...

Successful completion of the OPPIK project ” Transfer factor – research and development of a new dosage form of immunotherapeutic medicinal product “

31. 08. 2020

This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “Transfer factor – research and...

Successful completion of the OPPIK project “RESEARCH AND DEVELOPMENT OF A NEW WHOLE-CELL VACCINE AGAINST WHOOPING COUGH”

31. 08. 2020

This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “RESEARCH AND DEVELOPMENT OF A...

Achievements in current grants

02. 12. 2019

The project of innovative vaccine against whooping cough is in the terminal phase. The priority is the research and development...

Pharmaceutical production

12. 11. 2019

AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a...

Research and development of a new oral administration of the vaccine in the company AUMED, a.s.

21. 10. 2019

As part of the 4th public tender in the TRIO program, AUMED has a project for a new version of...

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s